Suchergebnisse - "Dal-Ré, Rafael"

PubPharm (288)

1

Is "interventional trial" a correct term to use in clinical research?

enthalten in: European journal of clinical pharmacology | 2024

von Dal-Ré, R.

2

Challenges in conducting efficacy trials for new COVID-19 vaccines in developed countries

enthalten in: Clinical trials (London, England) | 2024

von Dal-Ré, R. | Bottieau, E. | Launay, O. | +2

3

Peer-review : Considerations to Candal-Pedreira et al.'s proposals

enthalten in: Anales de pediatria | 2024

von Dal-Ré, R.

4

Is full transparency in clinical trials an achievable goal?

enthalten in: European journal of internal medicine | 2024

von Dal-Ré, R.

5

Current policies of non-commercial funders towards transparency in clinical trials

enthalten in: European journal of clinical investigation | 2024

von Dal-Ré, R.

6

Voluntary transparency of sponsors of medicines clinical trials is exceptional

enthalten in: Journal of clinical epidemiology | 2024

von Dal-Ré, R.

7

The definition of research misconduct should be stated in the abstract when reporting research on research misconduct

enthalten in: Accountability in research | 2024

von Dal-Ré, R. | Marušić, A.

8

COVID-19 research waste : An analysis on terminated clinical trials on medicines on ClinicalTrials.gov

enthalten in: European journal of internal medicine | 2023

von Dal-Ré, R.

CommentOn: JAMA. 2023 May 16;329(19):1695-1697. - PMID 37010865

9

Leading pharmaceutical companies lacked transparency on clinical trials' informed consent forms

enthalten in: Journal of clinical epidemiology | 2023

von Dal-Ré, R. | Voo, T. | Holm, S.

10

Posting of clinical trial results and other critical information from completed medicines trials on ClinicalTrials.gov

enthalten in: European journal of clinical pharmacology | 2023

von Dal-Ré, R. | Mahillo-Fernández, I.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]